Antibody engineering : methods and protocols /
Saved in:
| Edition: | 2nd ed. |
|---|---|
| Imprint: | New York : Humana Press : Springer, ©2012. |
| Description: | 1 online resource (xvi, 734 pages) : illustrations (some color) |
| Language: | English |
| Series: | Methods in molecular biology, 1940-6029 ; 907 Methods in molecular biology (Clifton, N.J.) ; v. 907. |
| Subject: | |
| Format: | E-Resource Book |
| URL for this record: | http://pi.lib.uchicago.edu/1001/cat/bib/11141272 |
MARC
| LEADER | 00000cam a2200000Ia 4500 | ||
|---|---|---|---|
| 001 | 11141272 | ||
| 005 | 20210625184228.5 | ||
| 006 | m o d | ||
| 007 | cr |n||||||||| | ||
| 008 | 120824s2012 nyua ob 001 0 eng d | ||
| 010 | |a 2012942124 | ||
| 016 | 7 | |a 101592844 |2 DNLM | |
| 019 | |a 964916625 |a 967620616 |a 985063528 |a 990528380 |a 1005835564 |a 1027576977 |a 1058926412 |a 1071344484 |a 1081244304 |a 1086939938 |a 1096232890 |a 1113295003 |a 1148166524 |a 1153019280 |a 1160100576 |a 1228586030 | ||
| 020 | |a 9781617799747 |q (electronic bk.) | ||
| 020 | |a 1617799742 |q (electronic bk.) | ||
| 020 | |a 1617799734 | ||
| 020 | |a 9781617799730 | ||
| 020 | |z 9781617799730 | ||
| 020 | |z 1617799734 | ||
| 024 | 3 | |a 9781617799730 | |
| 024 | 7 | |a 10.1007/978-1-61779-974-7 |2 doi | |
| 035 | |a (OCoLC)808157592 |z (OCoLC)964916625 |z (OCoLC)967620616 |z (OCoLC)985063528 |z (OCoLC)990528380 |z (OCoLC)1005835564 |z (OCoLC)1027576977 |z (OCoLC)1058926412 |z (OCoLC)1071344484 |z (OCoLC)1081244304 |z (OCoLC)1086939938 |z (OCoLC)1096232890 |z (OCoLC)1113295003 |z (OCoLC)1148166524 |z (OCoLC)1153019280 |z (OCoLC)1160100576 |z (OCoLC)1228586030 | ||
| 035 | 9 | |a (OCLCCM-CC)808157592 | |
| 037 | |a 1617799734 |b 00012511 | ||
| 040 | |a RML |b eng |e pn |c RML |d RML |d OCLCO |d GW5XE |d SCB |d COO |d FTU |d UBY |d OCLCA |d OCLCF |d YDXCP |d EUW |d OCLCQ |d OCL |d OCLCQ |d VT2 |d COF |d LVT |d MERER |d LIP |d OCLCO |d OCLCQ |d TFH |d OCLCO |d OCLCA |d BUF |d LND |d CEF |d CASUM |d OCLCQ |d U3W |d OCLCQ |d OCLCO |d OCLCQ |d OCLCO |d AU@ |d OCLCO |d OCLCQ |d YOU |d OCLCQ |d OCLCO |d TJC |d OCLCQ |d OCLCO |d OCLCQ |d OCLCO |d OCLCQ |d OCLCO |d OCLCQ |d OCLCO |d OCLCQ |d ADU |d WURST |d OCLCA |d OCLCQ |d OCLCO | ||
| 049 | |a MAIN | ||
| 050 | 4 | |a TP248.65.I49 |b A58 2012 | |
| 060 | 4 | |a W1 |b ME9616J v.907 2012 | |
| 060 | 4 | |a QW 525 | |
| 072 | 7 | |a MJCM |2 bicssc | |
| 072 | 7 | |a MED044000 |2 bisacsh | |
| 245 | 0 | 0 | |a Antibody engineering : |b methods and protocols / |c edited by Patrick Chames. |
| 250 | |a 2nd ed. | ||
| 260 | |a New York : |b Humana Press : |b Springer, |c ©2012. | ||
| 300 | |a 1 online resource (xvi, 734 pages) : |b illustrations (some color) | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 347 | |a text file | ||
| 347 | |b PDF | ||
| 490 | 1 | |a Methods in molecular biology, |x 1940-6029 ; |v 907 | |
| 504 | |a Includes bibliographical references and index. | ||
| 505 | 0 | 0 | |t Use of IMGT® databases and tools for antibody engineering and humanization / |r Marie-Paule Lefranc [and others] -- |t Computer-assisted modeling of antibody variable domains / |r Oscar H.P. Ramos -- |t Cloning single-chain antibody fragments (ScFv) from hyrbidoma cells / |r Lars Toleikis and André Frenzel -- |t Human in-cell scFv library from infiltrating B cell / |r Sylvie Peraldi-Roux -- |t Construction of human naive antibody gene libraries / |r Michael Hust [and others] -- |t Synthetic customized scFv libraries / |r Gautier Robin and Pierre Martineau -- |t Selection of stable scFv antibodies by phage display / |r Eeva-Christine Brockmann -- |t Generation of single domain antibody fragments derived from camelids and generation of manifold constructs / |r Cécile Vincke [and others] -- |t Generation and isolation of target-specific single-domain antibodies from shark immune repertoires / |r Mischa Roland Müller [and others] -- |t Generation of human single domain antibody repertoires by kunkel mutagenesis / |r Romain Rouet, Kip Dudgeon, and Daniel Christ -- |t Phage display and selections on purified antigens / |r Julie Matz and Patrick Chames -- |t Phage display and selections on cells / |r Klervi Even-Desrumeaux and Patrick Chames -- |t Humanization by CDR grafting and specificity-determining residue grafting / |r Jin Hong Kim and Hyo Jeong Hong -- |t Humanization by guided selections / |r Sang Jick Kim and Hyo Jeong Hong -- |t Selection of antibody fragments by yeast display / |r Nathalie Scholler -- |t Evolution of antibodies in vitro by ribosome display / |r Bryan M. Edwards and Mingyue He -- |t Mammalian cell surface display of full length IgG / |r Chen Zhou and Wenyan David Shen -- |t Production of antibody fragments in Escherichia coli / |r Tomohisa Katsuda [and others] -- |t Production of antibody derivatives in the methylotrophic yeast Pichia pastoris / |r Steve Schoonooghe, Jannick Leoen, and Jurgen Haustraete -- |t Monoclonal antibody expression in mammalian cells / |r Richard Yi Zhang and Wenyan David Shen -- |t Production of recombinant antibodies in Drosophila melanogaster S2 cells / |r Daniel X. Johansson, Thomas Krey, and Oskar Andersson -- |t Production of antibody fragments using the baculovirus-insect cell system / |r Takanori Furuta, Takafumi Ogawa, and Hideki Yamaji -- |t Transient and stable expression of antibodies in nicotiana species / |r Freydoun Garabagi, Michael D. McLean, and J. Christopher Hall -- |t Measuring antibody-antigen binding kinetics using surface plasmon resonance / |r Stephen Hearty, Paul Leonard, and Richard O'Kennedy -- |t Affinity determination of biotinylated antibodies by flow cytometry / |r Klervi Even-Desrumeaux and Patrick Chames -- |t Affinity maturation of antibodies : optimized methods to generate high-quality ScFv libraries and isolate IgG candidates by high-throughput screening / |r Laurence Renaut [and others] -- |t Affinity maturation by semi-rational approaches / |r Rodrigo Barderas [and others] -- |t Molecular scanning : combining random mutagenesis, ribosome display, and bioinformatic analysis for protein engineering / |r Alfredo Darmanin-Sheehan [and others] -- |t Fucose-targeted glycoengineering of pharmaceutical cell lines / |r Christiane Ogorek [and others] -- |t Fc engineering : design, expression, and functional characterization of antibody variants with improved effector function / |r Stefanie Derer [and others] -- |t Fc engineering : serum half-life modulation through FcRn binding / |r Tove Olafsen -- |t Monoclonal antibody lead characterization : in vitro and in vivo methods / |r Axel Hernandez [and others] -- |t Production, purification, and characterization of scFv TNF ligand fusion proteins / |r Andrea Fick, Agnes Wyzgol, and Harald Wajant -- |t Antibody-IL2 fusion proteins for tumor targeting / |r Andreas A. Hombach and Hinrich Abken -- |t Recombinant immunotoxins with low endotoxins for clinical and animal studies / |r Masanori Onda -- |t Chimeric antigen receptors for T-cell based therapy / |r Eleanor J. Cheadle [and others] -- |t Selection and use of intracellular antibodies (intrabodies) / |r Sandrine Moutel, Clément Nizak, and Franck Perez -- |t Radiolabeled antibodies for cancer imaging and therapy / |r Jacques Barbet [and others] -- |t Design and production of multimeric antibody fragments, focused on diabodies with enhanced clinical efficacy / |r Glenn A. Powers, Peter J. Hudson, and Michael P. Wheatcroft -- |t Production of bispecific antibodies : diabodies and tandem scFv / |r Nora Hornig and Aline Färber-Schwarz. |
| 588 | 0 | |a Online resource; title from PDF title page (Springer Protocols, viewed October 22, 2012). | |
| 520 | |a More than ever, antibodies are being recognized as a major drug modality in a variety of diseases, including cancer, autoimmune diseases, infectious diseases, or even neurodegenerative disorders. Over 30 therapeutic antibodies have been approved and novel molecules are entering clinical trials at an average rate of 50 per year and that is predicted to continue well into the future. Notwithstanding the many achievements already made in the field, there is still a lot of room for improvements for these molecules in terms of activity, and a plethora of approaches have been attempted to optimize these molecules. Antibody Engineering: Methods and Protocols, Second Edition was compiled to give complete and easy access to a variety of antibody engineering techniques, starting from the creation of antibody repertoires and efficient ways to select binders from these repertoires, to their production in various hosts, their detailed characterization using various well established techniques, and to the modification and optimization of these lead molecules in terms of binding activity, specificity, size, shape, and more. Written in the successful Methods in Molecular Biology series format, chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible protocols, and notes on troubleshooting and avoiding known pitfalls. Authoritative and easily accessible, Antibody Engineering: Methods and Protocols, Second Edition serves as an invaluable resource for both experts and those new to the field, and most of all as a source of inspiration for the creation of the antibodies of tomorrow. | ||
| 546 | |a English. | ||
| 650 | 0 | |a Immunotechnology |v Laboratory manuals. | |
| 650 | 2 | |a Publication Formats | |
| 650 | 2 | |a Investigative Techniques | |
| 650 | 2 | |a Biology. | |
| 650 | 2 | |a Genetic Engineering. | |
| 650 | 2 | |a Immunoglobulins. | |
| 650 | 2 | |a Immunoproteins. | |
| 650 | 2 | |a Analytical, Diagnostic and Therapeutic Techniques and Equipment | |
| 650 | 2 | |a Biological Science Disciplines. | |
| 650 | 2 | |a Publication Characteristics | |
| 650 | 2 | |a Serum Globulins. | |
| 650 | 2 | |a Genetic Techniques. | |
| 650 | 2 | |a Globulins. | |
| 650 | 2 | |a Blood Proteins. | |
| 650 | 2 | |a Natural Science Disciplines. | |
| 650 | 2 | |a Proteins. | |
| 650 | 2 | |a Disciplines and Occupations | |
| 650 | 2 | |a Amino Acids, Peptides, and Proteins | |
| 650 | 2 | |a Chemicals and Drugs | |
| 650 | 2 | |a Laboratory Manuals | |
| 650 | 2 | |a Methods. | |
| 650 | 2 | |a Genetics. | |
| 650 | 2 | |a Protein Engineering. | |
| 650 | 2 | |a Antibodies. | |
| 650 | 7 | |a Immunotechnology. |2 fast |0 (OCoLC)fst00968043 | |
| 653 | 0 | 0 | |a biomedische wetenschappen |
| 653 | 0 | 0 | |a biomedicine |
| 653 | 0 | 0 | |a immunologie |
| 653 | 0 | 0 | |a immunology |
| 653 | 0 | 0 | |a antilichamen |
| 653 | 0 | 0 | |a antibodies |
| 653 | 1 | 0 | |a Medicine (General) |
| 653 | 1 | 0 | |a Geneeskunde (algemeen) |
| 655 | 2 | |a Laboratory Manual. | |
| 655 | 4 | |a Electronic books. | |
| 655 | 7 | |a Laboratory manuals. |2 fast |0 (OCoLC)fst01920776 | |
| 700 | 1 | |a Chames, Patrick. |0 http://id.loc.gov/authorities/names/nb2012023795 | |
| 776 | 0 | 8 | |i Print version: |t Antibody engineering. |b 2nd ed. |d New York : Humana Press, ©2012 |z 9781617799730 |w (DLC) 2012942124 |w (OCoLC)810866017 |
| 830 | 0 | |a Methods in molecular biology (Clifton, N.J.) ; |v v. 907. |x 1064-3745 | |
| 903 | |a HeVa | ||
| 929 | |a oclccm | ||
| 999 | f | f | |i 42ab9e94-1cce-555c-8f4c-4ca31e77cac1 |s 2430ece6-aefb-5b96-95e7-5d51c80205bf |
| 928 | |t Library of Congress classification |a TP248.65.I49 A58 2012 |l Online |c UC-FullText |u https://link.springer.com/10.1007/978-1-61779-974-7 |z Springer Nature |g ebooks |i 12531741 | ||